<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273453</url>
  </required_header>
  <id_info>
    <org_study_id>582.2</org_study_id>
    <nct_id>NCT02273453</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets</brief_title>
  <official_title>A Randomised, Double-blind, Double-dummy, Placebo-controlled Cross-over Trial to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets (120 mg Valerian / 80 mg Lemon Balm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the presence of a hang-over effect in healthy volunteers the day after the&#xD;
      administration of Songha® Night&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test</measure>
    <time_frame>08:00h, 09:30h, 11:00h at Day 7 of each treament period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test</measure>
    <time_frame>up to day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective sleepiness rated on a 7 point scale</measure>
    <time_frame>up to day 36</time_frame>
    <description>Stanford Sleepiness Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective sleepiness measured on a visual analogue scale (VAS)</measure>
    <time_frame>up to day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality measured on a visual analogue scale (VAS)</measure>
    <time_frame>up to day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of tolerability by investigator on 4-point scale</measure>
    <time_frame>Day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of tolerability by patient on 4-point scale</measure>
    <time_frame>Day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 36 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Songha® Night</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Oxazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Songha® Night</intervention_name>
    <arm_group_label>Songha® Night</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxazepam</intervention_name>
    <arm_group_label>Placebo + Oxazepam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo + Oxazepam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female Caucasian subjects aged 20-60 years&#xD;
&#xD;
          -  Normal outcome in Pittsburgh Sleep Quality Index (PSQI), below mean +2 Standard&#xD;
             Deviation (SDs)&#xD;
&#xD;
          -  No manifest sleep disorder diagnosed by polysomnography&#xD;
&#xD;
          -  Normal pupillary function&#xD;
&#xD;
          -  Willing and able to give written informed consent in accordance with Good Clinical&#xD;
             Practice (GCP) and local legislation prior to participation in the study and able to&#xD;
             perform the study during the full time period of 36 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjective sleep duration of less than 3 hours in the night before the test&#xD;
&#xD;
          -  Caffeine, nicotine or alcohol on the day (from midnight) of the test&#xD;
&#xD;
          -  Alcohol consumption on the evening before visits 3, 5 or 7&#xD;
&#xD;
          -  Eye-drops or other drugs, taken orally or intravenously, influencing pupil size or&#xD;
             motility&#xD;
&#xD;
          -  Shift work&#xD;
&#xD;
          -  Drug and alcohol abuse&#xD;
&#xD;
          -  Use of psycho-active drugs during the past 30 days&#xD;
&#xD;
          -  Any treatment that might interfere with the evaluation of the test drug&#xD;
&#xD;
          -  Any drug known to interact with benzodiazepines and related drugs, e.g.&#xD;
             antiepileptics, antihistaminics, muscle relaxant drugs, antihypertensive drugs, drugs&#xD;
             inhibiting cytochrome P450&#xD;
&#xD;
          -  Any serious disorder that might interfere with his/her participation in this study and&#xD;
             the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency,&#xD;
             hepatic or metabolic dysfunction, cardiovascular disease, psychiatric disorder,&#xD;
             myasthenia gravis, delirious state, etc.)&#xD;
&#xD;
          -  Known hypersensitivity to any of the ingredients of the study drugs&#xD;
&#xD;
          -  Pregnant or nursing women or inadequate birth control methods (this applies to female&#xD;
             of childbearing potential only)&#xD;
&#xD;
          -  Participation in another trial within the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

